Summit Clinical Research

07/21/2025

Through July 18, Summit has screened 3,180 participants and randomized 901 across active liver and metabolic studies. That’s a 28 percent screen-to-randomization rate, which is well above typical performance for complex liver and metabolic trials.

We’ve hit as many as 62 randomizations in a single week, and we’re seeing that level of performance more than once.

These results reflect the strength of our site network, the consistency of our teams, and the focus we bring to every trial we support.

07/14/2025

is a KOL-led Integrated Research Organization focused on liver, metabolic, and neurodegenerative diseases.

We combine deep scientific expertise with scalable operational services to accelerate clinical trials that matter.

From protocol design to site activation and patient recruitment, we help sponsors move faster, smarter, and with greater confidence.

Ready to accelerate your next trial? Learn more at https://summitclinicalresearch.com/

07/11/2025

✈️ Next stop: Boston.

Summit Clinical Research is heading to the Obesity & Weight Loss Drug Development Summit as an Innovation Partner and can’t wait to connect.

Our booth will also feature members of the team from Pinnacle Clinical Research. Stop by Booth #2 and say hello. We’re looking forward to conversations that move obesity research forward.

📅 July 14–16 | 📍 Booth #2

https://lnkd.in/dfvvG26W

07/08/2025

Boston, we’re coming your way!

Summit Clinical Research is attending the Obesity & Weight Loss Drug Development Summit next week, and we’re excited to connect with industry leaders shaping the future of obesity care.

Attending on our behalf:

• Dave Rosa, Director of Business Development

• Our site partners at Pinnacle Clinical Research:
• Dr. Rashmee Patil, CEO & Hepatologist
• Dr. Dimple Desai, PI & South Texas Medical Director (Brownsville)
• Dan Duffy, CEO

📍 Visit us at Booth #2 and say hello.

📅 July 14–16 | Boston, MA
https://obesity-weight-loss-summit.com/

Companies Attending Include: Harnessing Novel Targets & GLP Combination Therapies to Improve Efficacy & Tolerability for Longer Lasting Clinical Outcomes EVENT GUIDE REGISTER PARTNER Advancing Best-In Class Weight Loss Therapies in the Evolving Obesity Landscape The 3rd Obesity & Weight Loss Drug De...

07/04/2025

From all of us at Summit Clinical Research — Happy Fourth of July.
Hope you get a chance to relax, recharge, and enjoy the day with the people who matter most.

06/30/2025

Dr. Naim Alkhouri, our Chief Academic Officer at Summit Clinical Research, was recently featured on Good Morning America to talk about fatty liver disease.

He discussed MASLD and MASH, along with new treatment options like Rezdiffra and GLP-1 drugs that are giving patients real hope. The segment also featured a patient story, making it clear just how important early awareness and access to care really are.

This kind of national spotlight helps move the conversation forward—and we’re proud to see Summit at the heart of it.

📺 Watch the full segment: https://www.goodmorningamerica.com/amp/video/123006818


Pharmaceuticals Novo Nordisk Eli Lilly and Company

06/27/2025

Obesity is a global health challenge, but also a frontier for groundbreaking innovation.

The Obesity & Weight Loss Drug Development Summit tackles urgent questions in drug development, patient outcomes, and the future of care.

As an Innovation Partner, is committed to driving better, faster, and more effective clinical trials for obesity and metabolic disease.

Learn more about the event and why we’re proud to support it:
🔗 obesity-weight-loss-summit.com

06/25/2025

𝗝𝘂𝘀𝘁 𝗱𝗮𝘆𝘀 𝗮𝘄𝗮𝘆 - Summit Clinical Research and Xtalks invite you to join a forward-looking discussion on noninvasive diagnostics in MASLD/MASH clinical trials

Discover how advanced tools like VCTE and data from the ESSENCE and SYMMETRY trials are changing how we detect, stratify, and treat steatotic liver disease.

Hear from leading voices in hepatology:
• Dr. Naim Alkhouri, Summit Clinical Research
• Dr. Mazen Noureddin, Summit Clinical Research
• Dr. Samer Gawrieh, Indiana University

Don’t miss this chance to gain real-world insights into the future of MASLD/MASH research

Register now: https://xtalks.com/webinars/advancing-masld-mash-clinical-trials-the-role-of-non-invasive-diagnostics/

06/19/2025

𝗔𝗿𝗲 𝘄𝗲 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝘁𝗿𝗲𝗮𝘁𝗶𝗻𝗴 𝗠𝗲𝘁𝗔𝗟𝗗 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗿𝗲𝗮𝗹𝗶𝘇𝗶𝗻𝗴 𝗶𝘁?

In our recent Xtalks webinar, Dr.Brian P Lee, Dr. Mazen Noureddin, Dr. Naim Alkhouri, and Dr. uan Pablo Arab explored what happens when alcohol use and metabolic dysfunction overlap. The panel shared insights on disease progression, trial design, patient inclusion, and how real-world alcohol use may be more common in MASH populations than previously assumed.

One segment uncovered unexpected data from a major trial. Another challenged the traditional boundaries between and . If you work in liver disease research, this is a conversation worth watching.

The full replay is now available.
📺 Watch the replay here: https://xtalks.com/webinars/metabolic-and-alcohol-associated-liver-disease-metald-ald-an-emerging-mash-drug-development-field/

06/19/2025

🎉 Congratulations to Jeanne Stange, Human Resources Manager, on her 2nd at ! 🥳

06/18/2025

Summit Clinical Research is proud to be an Innovation Partner at the 3rd Annual Obesity & Weight Loss Drug Development Summit, taking place July 14–16 in Boston.

This event unites top minds in metabolic health and obesity research, and we’re thrilled to be part of it. Stay tuned for more details about our team’s involvement.

🔗 https://obesity-weight-loss-summit.com/

06/16/2025

𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗠𝗔𝗦𝗟𝗗 𝗠𝗔𝗦𝗛 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀: 𝗧𝗵𝗲 𝗥𝗼𝗹𝗲 𝗼𝗳 𝗡𝗼𝗻𝗶𝗻𝘃𝗮𝘀𝗶𝘃𝗲 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀

How can noninvasive tools like VCTE reshape the future of liver disease research? Join Summit Clinical Research and Xtalks on June 30 for a free webinar that dives deep into the clinical applications of noninvasive diagnostics in MASLD MASH trials.

Dr. Naim Alkhouri, Dr. Mazen Noureddin, and Dr. Samer Gawrieh will share:
✔️ Insights from the ESSENCE and SYMMETRY trials
✔️ How liver stiffness trends relate to disease progression
✔️ The growing role of noninvasive tests in patient stratification and clinical decision making

This is a must attend session for anyone advancing diagnostics, trial design, or care strategies in steatotic liver disease.

📅 Monday, June 30 at 12pm EDT

🔗 Register: https://xtalks.com/webinars/advancing-masld-mash-clinical-trials-the-role-of-non-invasive-diagnostics/

📄 Read the press release: https://www.prweb.com/releases/advancing-masldmash-clinical-trials-the-role-of-non-invasive-diagnostics-upcoming-webinar-hosted-by-xtalks-302481652.html